Loading
Life sciences · Review
International Journal of Innovative Technologies in Social Science · September 9, 2026
Raises a question worth testing. It does not answer one.
This narrative review collates existing literature on cardamom across multiple purported health domains—metabolic, cardiovascular, gastrointestinal, oncological, and neuroprotective—but does not quantify evidence strength or identify which claims rest on robust human data versus mechanistic or animal studies. The review identifies antioxidant and anti-inflammatory pathways as primary mechanisms and highlights inconsistencies in human clinical data, particularly for obesity and cholesterol, indicating that current evidence does not yet support clinical translation.
Narrative review. Not specified; review includes human clinical trials, animal models, and in vitro studies without explicit population definition.. Intervention: Green cardamom (Elettaria cardamomum) and its constituents evaluated across metabolic, cardiovascular, gastrointestinal, oncological, neuroprotective, and antimicrobial domains..
Green cardamom consistently improves insulin resistance, endothelial function, and triglyceride levels in metabolic and cardiovascular contexts Human clinical data on cardamom's effects on obesity indexes and total cholesterol remain inconsistent In vitro and animal models show promising results for Alzheimer's disease and anxiety management
No data on adverse effects, contraindications, or optimal dosing for any application. Cardamom exhibits selective cytotoxicity against triple-negative breast cancer in oncological research
Clinicians should recognize that while cardamom has been used historically in Ayurvedic medicine for respiratory and digestive health and shows promise in mechanistic studies, most claims lack sufficient human trial data or consistent clinical evidence to guide therapeutic recommendations. The inconsistency in human data on metabolic endpoints suggests caution in extrapolating from preclinical findings.
This narrative review synthesizes mechanistic and preclinical evidence across disparate disease areas without meta-analysis, systematic quantification, or human clinical trial data sufficient to support clinical recommendations; it raises questions about cardamom's therapeutic potential rather than answering them definitively.
As stated by the source record.
Clinicians should recognize that while cardamom has been used historically in Ayurvedic medicine for respiratory and digestive health and shows promise in mechanistic studies, most claims lack sufficient human trial data or consistent clinical evidence to guide therapeutic recommendations. The inconsistency in human data on metabolic endpoints suggests caution in extrapolating from preclinical findings.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background: Green cardamom is the dried fruit of the herbaceous plant Elettaria cardamomum, originating from India. Due to its rich heritage in Ayurvedic medicine, mostly as a respiratory and digestive aid, as well as its distinct flavour, it has been historically known as the „Queen of Spices”. Despite its comprehensive pharmacological profile, green cardamom is frequently overshadowed by other functional spices, such as turmeric or cinnamon. Purpose: This narrative review aims to evaluate current evidence on green cardamom’s clinical therapeutic efficacy, with emphasis on metabolic, cardiovascular and gastrointestinal health, as well as potential anti-cancer and neuroprotective properties. Methods: A comprehensive review of literature was performed, using databases such as PubMed and Google Scholar. Relevant articles were found, including human clinical trials, animal models, in vitro studies, meta-analyses and systematic reviews. Results: Current evidence suggests that green cardamom’s therapeutic effects are primarily mediated through antioxidant and anti-inflammatory pathways. In metabolic and cardiovascular contexts, cardamom consistently improves insulin resistance, endothelial function, triglyceride levels and provides cardioprotection during ischemic events. However, human clinical data regarding its effects on obesity indexes and total cholesterol remain inconsistent. Gastrointestinally, the spice acts as both a spasmogenic and spasmolytic agent and offers protection against gastric ulcers. Oncological research highlights cardamom’s selective cytotoxicity, particularly against triple-negative breast cancer. In in vitro and animal models, the spice has shown promising results in management of Alzheimer’s disease and anxiety. Furthermore, its essential oil exhibits broad-spectrum antimicrobial activity.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.